The risk of incident atrial fibrillation in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors: a nationwide cohort study

The risk of incident atrial fibrillation in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors: a nationwide cohort study

Abstract Background Although a few meta-analyses were conducted to compare the risk of incident atrial fibrillation (AF) between sodium-glucose cotransporter-2 inhibitor (SGLT2i), glucagon-like peptide-1 receptor agonists (GLP-1RA), and other anti-hyperglycemic agents using indirect or direct compar...

Full description

Bibliographic Details
Main Authors: Yi-Hsin Chan, Tze-Fan Chao, Shao-Wei Chen, Hsin-Fu Lee, Pei-Ru Li, Wei-Min Chen, Yung-Hsin Yeh, Chi-Tai Kuo, Lai-Chu See, Gregory Y. H. Lip
Format: Article
Language:English
Published: BMC 2022-06-01
Series:Cardiovascular Diabetology
Subjects:
Atrial fibrillation
Type 2 diabetes mellitus
Sodium-glucose cotransporter-2 inhibitor
Glucagon-like peptide-1 receptor agonist
Dipeptidyl peptidase-4 inhibitor
Online Access:https://doi.org/10.1186/s12933-022-01549-x

Internet

https://doi.org/10.1186/s12933-022-01549-x

Similar Items